The majority of driver mutations are targetable by the EGFR tyrosine kinase inhibitors (TKIs) (e.g. gefitinib, erlotinib, afatinib, and osimertinib in EGFR-mutant NSCLC; crizotinib, ceritinib, brigatinib, lorlatinib, and alectinib in ALK rearranged tumours; crizotinib in ROS1 rearranged disease). This evidence concerns the gene ALK and non-small cell lung carcinoma.